- Home
- HIX vs AVIR Comparison
HIX vs AVIR Comparison
Compare HIX & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIX | AVIR |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | 55 |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.5M | 434.5M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HIX | AVIR |
|---|---|---|
| Price | $3.91 | $5.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 319.7K | 227.9K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.75 | $2.46 |
| 52 Week High | $4.39 | $6.45 |
Technical Indicators
Market Signals| Indicator | HIX | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 46.30 |
| Support Level | $3.90 | $5.13 |
| Resistance Level | $4.26 | $6.37 |
| Average True Range (ATR) | 0.05 | 0.23 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 13.16 | 37.29 |
Price Performance
Historical ComparisonAbout HIX Western Asset High Income Fund II Inc.
Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its investment objective is to maximize current income by investing at least 80% of its net assets and borrowings for investment purposes in high-yield debt securities.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.